Table 3.
Total (N=2191)* | Among women who reported positive or negative status (N=1618)†; | |||||
---|---|---|---|---|---|---|
OR | 95% Cl | p-value | OR | 95% Cl | p-value | |
Age at Diagnosis | ||||||
41–50 vs. ≤40 | 1.18 | 0.79–1.76 | 0.425 | 0.78 | 0.40–1.52 | 0.466 |
51–64 vs. ≤40 | 1.61 | 1.10–2.37 | 0.015 | 1.09 | 0.59–2.03 | 0.787 |
Stage at Diagnosis | ||||||
Regional vs. Local | 1.00 | 0.81–1.24 | 0.979 | 1.15 | 0.76–1.74 | 0.509 |
Distant vs. Local | 1.15 | 0.59–2.22 | 0.689 | 2.72 | 1.06–6.97 | 0.037 |
Unstaged/Unknown vs. Local | 1.70 | 0.70–4.16 | 0.245 | --- | ||
Education | ||||||
High School vs. Higher education | 2.60 | 2.11–3.21 | <0.001 | 1.49 | 0.97–2.28 | 0.070 |
Race | ||||||
Non-white vs. white | 3.12 | 2.26–4.31 | <0.001 | 2.55 | 1.38–4.69 | 0.003 |
Household Income | ||||||
30–70K vs. >70K | 1.31 | 1.02–1.68 | 0.032 | 0.85 | 0.54–1.32 | 0.459 |
<30K vs. >70K | 2.89 | 2.18–3.82 | <0.001 | 0.87 | 0.48–1.59 | 0.650 |
Hormone receptor status (registry) | ||||||
ER/PR negative vs. positive | 1.62 | 1.27–2.06 | <0.001 | 2.66 | 1.76–4.02 | <0.001 |
Discordant N=690 vs. Concordant N=1501
Excludes don’t know/missing self-report, Discordant N=117 vs. Concordant N=1501